News Release

New study to test drugs for early COVID-19 infection

Trial will evaluate the effectiveness of ivermectin, metformin and fluvoxamine on preventing COVID-19 disease progression

Business Announcement

McMaster University

Hamilton, ON (February 9, 2021) - McMaster University researchers are leading a large international study to test drugs to treat COVID-19 patients.

The trial will evaluate the effectiveness of ivermectin, metformin and fluvoxamine on preventing COVID-19 disease progression, and the researchers say the results could be known in as short a time as two to three months.

These drugs have shown mixed results in previous studies but have not been tested in a large clinical trial, said Edward Mills, principal investigator of the Together COVID-19 trial and a McMaster professor of health research methods, evidence, and impact.

"The need for treatments in early disease is paramount. Evidence is quickly emerging that suggests a number of drugs may have a promising effect on reducing COVID-19 disease severity in patients with mild to moderate disease," said Mills. "Our study has been designed to rapidly recruit patients to evaluate these potential therapeutics."

The McMaster research team is partnering with research clinic Cardresearch and the Pontifical Catholic University of Minas Gerais in Brazil as well as the University of Stellenbosch in South Africa on an ongoing clinical trial established to answer multiple questions of drug effectiveness over time.

The study is funded in part by the Bill and Melinda Gates Foundation and Fastgrants, a collaboration of technology philanthropists.

The clinical trial is important because although COVID-19 vaccines are being rolled out in high-income countries, it may be years before the vaccines are universally available for low- and middle-income countries, Mills said.

"For this reason, the Together COVID-19 trial was created to evaluate the effectiveness of cheap, widely available drugs in low- and middle-income countries that can be repurposed for COVID-19," he said.

There are eighteen study sites in Brazil where more than 229,000 have died of the virus since the beginning of the pandemic.

"For Brazil, the high incidence of COVID-19 and no proven therapies on early disease move patients towards study participation," said co-investigator Gilmar Reis, director of the outpatient research clinic at Cardresearch and associate professor of medicine at Pontifical Catholic University of Minas Gerais.

"There is particularly keen interest in our trial for its evaluation of ivermectin," he added.

Ivermectin is an inexpensive drug costing less than $5 per treatment which is on the list of essential medicines published by the World Health Organization. Ivermectin is typically used to treat parasitic infections, however emerging evidence from smaller clinical trials may indicate a benefit for COVID-19 patients with early disease.

The study is also evaluating metformin, a drug widely used to treat diabetes, and fluvoxamine a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression and anxiety disorders.

It is anticipated that there will be up to 3,200 participants in the trial. It the study recruits patients at the same rate as its first evaluations, there could be results within three to six months, said Mills.

"As the pandemic continues with no end in sight for many low- and middle-income countries, there is a growing urgency for effective therapies. This could be a real game-changer," he said.

"Many countries simply do not have the health care resources to continue the current rate of patients being admitted to hospital with COVID-19. The Together trial hopes to help identify therapies, of repurposed drugs known for decades to be safe, to slow the pandemic while many countries await the delivery of vaccines."


For more information:

Please contact:
Veronica McGuire
Media Relations
Faculty of Health Sciences
McMaster University

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.